<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="58612">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01778634</url>
  </required_header>
  <id_info>
    <org_study_id>HP-00054998</org_study_id>
    <secondary_id>R01HD067126</secondary_id>
    <nct_id>NCT01778634</nct_id>
  </id_info>
  <brief_title>Trial of Intravenous Azithromycin to Eradicate Ureaplasma Respiratory Tract Infection in Preterm Infants</brief_title>
  <acronym>AZIPIII</acronym>
  <official_title>A Phase IIb Randomized, Placebo-controlled, Double-blind Trial of Azithromycin to Eradicate Ureaplasma Respiratory Tract Infection in Preterm Infants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rose Viscardi, MD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Mercy Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Virginia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Alabama at Birmingham</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Oregon Health and Science University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Maryland</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether intravenous azithromycin is effective in
      eradicating Ureaplasma respiratory tract infection in preterm infants born at 24 to 28 weeks
      gestation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study design will be a double-blind, placebo-controlled clinical trial to test the
      efficacy and safety of azithromycin 20 mg/kg x 3 days to eradicate Ureaplasma spp from the
      respiratory tract of preterm infants 24 weeks 0 days to 28 weeks 6 days gestation exposed to
      positive pressure ventilation. The primary outcome will be survival with microbiological
      eradication of Ureaplasma defined as survival to discharge or transfer with 3 negative
      cultures obtained post-therapy. Secondary outcomes will include physiologic BPD at 36 weeks
      post-menstrual age (PMA), overall mortality, incidence of co-morbidities of prematurity such
      as intraventricular hemorrhage, periventricular leukomalacia, necrotizing enterocolitis,
      bacterial and fungal nosocomial infection, pulmonary air leak, patent ductus arteriosus,
      retinopathy of prematurity, number of days of positive pressure ventilation, number of days
      of oxygen supplementation, use of postnatal steroids, and use of non-study antibiotics. At 6
      and 18 months adjusted age, a pulmonary outcome questionnaire will be administered by phone
      or in person interview. At 18-22 months adjusted age, neurodevelopmental outcomes will be
      assessed by 1) Bayley Scale of Infant and Toddler Development, 3rd edition (BSID-III); 2)
      Amiel-Tison neurologic examination; 3) Gross Motor Function Classification System; and 4)
      medical record review for hearing impairment with or without amplification and vision
      impairment (vision &lt;20/200).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2013</start_date>
  <completion_date type="Anticipated">December 2016</completion_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Survival with microbiological eradication of Ureaplasma</measure>
    <time_frame>Participants will be followed for the duration of hospital stay, an expected average of 10 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Bacterial clearance (eradication) will be defined as 3 negative cultures obtained 2 and 5 days post-third dose and 21 d of age. Survival is defined as survival at time of discharge or transfer from the neonatal intensive care unit (NICU).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Physiologic defined bronchopulmonary dysplasia (BPD) at 36 weeks post menstrual age</measure>
    <time_frame>36 weeks post menstrual age (one month prior to due date)</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Physiologic definition of BPD based on oxygen-saturation monitoring</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Death or Neurodevelopmental impairment</measure>
    <time_frame>22-26 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Neurodevelopmental impairment will be assigned if any of the following are present at 22-26 months adjusted age: moderate to severe cerebral palsy, bilateral blindness, bilateral hearing impairment requiring amplification, Gross Motor Function Classification System score ≥ 2, or Bayley Scale of Infant and Toddler Development, 3rd edition (BSID-III) cognitive or motor score &lt;70.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulmonary impairment</measure>
    <time_frame>6-26 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Parent report of recurrent wheezing and/or chronic cough</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Death</measure>
    <time_frame>22-26 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Mortality from any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of positive pressure support</measure>
    <time_frame>Participants will be followed for the duration of hospital stay, an expected average of 10 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Combined number of days receiving mechanical ventilation plus non-invasive modes of positive pressure support.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of oxygen supplementation</measure>
    <time_frame>Participants will be followed for the duration of hospital stay, an expected average of 10 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Receipt of supplemental oxygen</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Air leaks</measure>
    <time_frame>Participants will be followed for the duration of hospital stay, an expected average of 10 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Any pulmonary air leak (pulmonary interstitial emphysema, pneumothorax, pneumomediastinum) confirmed by chest x-ray</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Received postnatal steroids</measure>
    <time_frame>36 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Receipt of steroid medications (hydrocortisone, dexamethasone)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Received Non-Study antibiotics</measure>
    <time_frame>Participants will be followed for the duration of hospital stay, an expected average of 10 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Received Non-study antibiotics following study drug intervention period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK)/Pharmacodynamics (PD) modelling of time course of azithromycin plasma concentrations</measure>
    <time_frame>Study day 1-day 7</time_frame>
    <safety_issue>No</safety_issue>
    <description>Population PK model will be refined with additional plasma concentrations in 15 subjects who receive azithromycin.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Threshold Retinopathy of Prematurity (ROP)</measure>
    <time_frame>Participants will be followed for the duration of hospital stay, an expected average of 10 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Threshold ROP requiring surgical intervention as diagnosed by ophthalmologic examination</description>
  </other_outcome>
  <other_outcome>
    <measure>Necrotizing enterocolitis (NEC)</measure>
    <time_frame>Participants will be followed for the duration of hospital stay, an expected average of 10 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Necrotizing enterocolitis ≥ Bell Stage II by radiographic and clinical criteria.</description>
  </other_outcome>
  <other_outcome>
    <measure>Infections</measure>
    <time_frame>Participants will be followed for the duration of hospital stay, an expected average of 10 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Culture-confirmed bacterial or fungal infection based on culture from sterile site (blood, cerebral spinal fluid, or urine)</description>
  </other_outcome>
  <other_outcome>
    <measure>Severe Intraventicular hemorrhage (IVH)</measure>
    <time_frame>Participants will be followed for the duration of hospital stay, an expected average of 10 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Grade III or IV IVH confirmed by cranial ultrasound</description>
  </other_outcome>
  <other_outcome>
    <measure>Periventricular leukomalacia (PVL)</measure>
    <time_frame>Participants will be followed for the duration of hospital stay, an expected average of 10 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Cranial ultrasound confirmed PVL</description>
  </other_outcome>
  <other_outcome>
    <measure>Patent ductus arteriosus (PDA)</measure>
    <time_frame>14 days</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Detection of PDA by cardiac echocardiogram with left to right shunting, or clinical evidence of murmur, bounding pulses, and widened pulse pressure.</description>
  </other_outcome>
  <other_outcome>
    <measure>Cardiac arrhythmia</measure>
    <time_frame>3 days</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>EKG evidence of prolonged QT (QTc &gt; 450 ms)</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">180</enrollment>
  <condition>Ureaplasma Infections</condition>
  <arm_group>
    <arm_group_label>Placebo (5% dextrose)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Azithromycin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Azithromycin intravenous (2 mg/ml) 20 mg/kg every 24h x 3 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Azithromycin</intervention_name>
    <description>Azithromycin intravenous 20 mg/kg every 24 h x 3 days</description>
    <arm_group_label>Azithromycin</arm_group_label>
    <other_name>Zithromax</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo (for azithromycin)</intervention_name>
    <arm_group_label>Placebo (5% dextrose)</arm_group_label>
    <other_name>equal volume of 5% dextrose water</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Appropriate size for gestational age (AGA)

          -  Gestational age 24 weeks 0 days-28weeks 6 days by best obstetrical estimate

          -  &lt;72 h age

          -  Positive pressure ventilation for at least 1 hour duration during the first 72 hours
             of life

          -  Presence of indwelling intravenous line for drug administration

        Exclusion Criteria:

          -  Any patient judged to be non-viable or for whom withdrawal of life support is planned

          -  Patients with major lethal congenital anomalies

          -  Triplets or higher order multiples

          -  Patients delivered for maternal indications (low risk of Ureaplasma colonization)

          -  Patients with EKG QT interval corrected for heart rate (Qtc) ≥ 450 ms

          -  Patients with significant hepatic impairment (direct bilirubin &gt;1.5 mg/dL)

          -  Patients exposed to other systemic macrolide

          -  Patients with clinically suspected Ureaplasma central nervous system (CNS) infection
             or other confirmed bacterial/viral infection

          -  Patients participating in other clinical trials involving investigational products.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>72 Hours</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rose M Viscardi, M.D.</last_name>
    <role>Study Chair</role>
    <affiliation>University of Maryland</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Pamela Donohue, ScD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Namasivayam Ambalavanan, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Alabama at Birmingham</affiliation>
  </overall_official>
  <overall_official>
    <last_name>David A Kaufman, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Virginia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Robert Schelonka, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oregon Health and Science University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Michael L Terrin, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Maryland</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Susan J Dulkerian, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mercy Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Rose M Viscardi, M.D.</last_name>
    <phone>410-706-1913</phone>
    <email>rviscard@umaryland.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Michael L Terrin, M.D.</last_name>
    <phone>410-706-6139</phone>
    <email>mterrin@epi.umaryland.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35249-7335</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Namasivayam Ambalavanan, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Maryland School of Medicine</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Rose M Viscardi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Michael L Terrin, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Laurence S Magder, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mercy Medical Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins University</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Susan Aucott, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pamela Donohue, ScD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oregon Health Sciences University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239-3098</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Robert Schelonka, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Cindy McEvoy, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Virginia</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22908-0386</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>David A Kaufman, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Hassan HE, Othman AA, Eddington ND, Duffy L, Xiao L, Waites KB, Kaufman DA, Fairchild KD, Terrin ML, Viscardi RM. Pharmacokinetics, safety, and biologic effects of azithromycin in extremely preterm infants at risk for ureaplasma colonization and bronchopulmonary dysplasia. J Clin Pharmacol. 2011 Sep;51(9):1264-75. doi: 10.1177/0091270010382021. Epub 2010 Nov 23.</citation>
    <PMID>21098694</PMID>
  </reference>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 30, 2014</lastchanged_date>
  <firstreceived_date>January 22, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Maryland</investigator_affiliation>
    <investigator_full_name>Rose Viscardi, MD</investigator_full_name>
    <investigator_title>Professor of Pediatrics</investigator_title>
  </responsible_party>
  <keyword>Ureaplasma parvum</keyword>
  <keyword>Ureaplasma urealyticum</keyword>
  <keyword>prematurity</keyword>
  <keyword>bronchopulmonary dysplasia</keyword>
  <keyword>azithromycin</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Respiratory Tract Infections</mesh_term>
    <mesh_term>Ureaplasma Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Azithromycin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
